Common Contracts

1 similar Target Discovery Collaboration and License Agreement contracts

Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies
Target Discovery Collaboration and License Agreement • August 2nd, 2022

IRVING, Texas and MONROVIA, Calif., Aug. 2, 2022 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, and Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, announced today a multi-year strategic option and license agreement to research, develop and commercialize XmAb® bispecific antibodies directed against novel targets for the treatment of patients with cancer.

AutoNDA by SimpleDocs
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!